Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
PaperCitations, authors & open-access status
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 86 citations, 2019 year and bronze oa status.
86
Citations
2019
Year
bronze
OA Status